Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals Inc Frequently Asked Questions
What is the ticker symbol for Olema Pharmaceuticals Inc? What does OLMA stand for in stocks?
OLMA is the stock ticker symbol of Olema Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Olema Pharmaceuticals Inc (OLMA)?
As of Fri Nov 01 2024, market cap of Olema Pharmaceuticals Inc is 666.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of OLMA stock?
You can check OLMA's fair value in chart for subscribers.
Is Olema Pharmaceuticals Inc a good stock to buy?
The fair value guage provides a quick view whether OLMA is over valued or under valued. Whether Olema Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Olema Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OLMA.